Search

Your search keyword '"Stipanov, Michael"' showing total 7 results
Start Over Author "Stipanov, Michael"
7 results on '"Stipanov, Michael"'

2. Immunization With Mutant p53- and K-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome

Author

Carbone, David P., Ciernik, I Frank, Kelley, Michael J., Smith, M Charles, Nadaf, Sorena, Kavanaugh, Denise, Maher, V Ellen, Stipanov, Michael, Contois, David, Johnson, Bruce E., Pendleton, C David, Seifert, Burkhardt, Carter, Charley, Read, Elizabeth J., Greenblatt, Jay, Top, Lois E., Kelsey, Morris I., Minna, John D., and Berzofsky, Jay A.

Published
2005
Full Text
View/download PDF

3. Identifying and interpreting actionable molecular alterations from next-generation sequencing results in the community: A Sarah Cannon molecular cancer conference.

Author

Dilks, Holli Hutcheson, primary, McKenzie, Andrew, additional, Jones, Suzanne Fields, additional, Daniel, Davey B., additional, Arrowsmith, Edward, additional, Stipanov, Michael A., additional, Anz, Bertrand Marquess, additional, Johnson, Darrell, additional, Tran, An, additional, Nadeau, Benjamin Rolland, additional, Krueger, Sylvia Lynne, additional, Daniel, Brooke R., additional, Holland, Derek Weldon, additional, Tucker, Kimberly, additional, Correll, Mick, additional, Spigel, David R., additional, and Burris, Howard A., additional

Published
2018
Full Text
View/download PDF

7. Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium.

Author

Hainsworth, John D., Meluch, Anthony A., Lane, Cassie M., Spigel, David R., Burris III, Howard A., Gandhi, Jitendra G., Crane, Edward J., Stipanov, Michael A., and Greco, F. Anthony

Subjects
PROSTATE cancer, CASTRATION, CANCER patients, CANCER treatment, EXOCRINE glands
Abstract

Patients with metastatic prostate cancer resistant to hormones and docetaxel were treated with vinflunine (320 mg/m2 every 21 days), a new vinca alkaloid with improved preclinical activity. Only 1 of 36 patients (3%) had partial response; the median progression-free survival (PFS) was 2.1 months. Treatment was well tolerated, with myelosuppression as the only frequent toxicity. Vinflunine has a low level of activity in the treatment of refractory metastatic prostate cancer, and should not be further developed for this indication. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results